Chemical-Scale Studies on the Role of a Conserved Aspartate in Preorganizing the Agonist Binding Site of the Nicotinic Acetylcholine Receptor by Cashin, Amanda L. et al.
Chemical-Scale Studies on the Role of a Conserved Aspartate in
Preorganizing the Agonist Binding Site of the Nicotinic
Acetylcholine Receptor
Amanda L. Cashin†, Michael M. Torrice†, Kathryn A. McMenimen, Henry A. Lester, and
Dennis A. Dougherty*
Division of Chemistry and Chemical Engineering and Division of Biology, California Institute of
Technology, Pasadena, CA 91125 USA
Abstract
The nicotinic acetylcholine receptor and related Cys-loop receptors are ligand-gated ion channels
that mediate fast synaptic transmission throughout the central and peripheral nervous system. A
highly conserved aspartate residue (D89) that is near the agonist binding site, but does not directly
contact the ligand, plays a critical part in receptor function. Here we probe the role of D89 using
unnatural amino acid mutagenesis coupled with electrophysiology. Homology modeling
implicates several hydrogen bonds involving D89. We find that no single hydrogen bond is
essential to proper receptor function. Apparently the side chain of D89 establishes a redundant
network of hydrogen bonds; these bonds preorganize the agonist binding site by positioning a
critical tryptophan residue that directly contacts the ligand. Earlier studies of the D89N mutant led
to the proposal that a negative charge at this position is essential for receptor function. However,
we find that receptors with neutral side chains at position 89 can function well, if the side chain is
less perturbing than the amide of asparagine (nitro or keto groups allow function), or if a
compensating backbone mutation is made to relieve unfavorable electrostatics.
Neuroreceptors are central players of synaptic transmission, receiving and interpreting
chemical signals between neurons in the nervous system. Neuroreceptors of the ligand-gated
ion channel (LGIC) family convert incoming chemical signals into electrical output. In the
LGIC gating process, neurotransmitters are recognized by ligand-binding domains, and
binding triggers conformational changes within the structure to form an ion-conducting
pore.
The nicotinic acetylcholine receptor (nAChR) has served as a prototype for understanding
the structure and function of the Cys-loop family of LGICs (also known as pentameric
LGICs). In this superfamily of receptors, which also includes γ-aminobutyric acid, glycine,
and serotonin receptors, the five subunits are symmetrically or pseudosymmetrically
arranged around a central ion-conducting pore. Each subunit contains a four-helix
transmembrane domain that contains the ion channel gate and an extracellular ligand-
binding domain. Members of nAChR family are expressed at the neuromuscular junction
and in the electric organ of eels and rays (muscle-type receptors), as well as in the central
nervous system (neuronal receptors). The muscle-type receptor is the best characterized, and
the form studied here is the embryonic muscle nAChR, with a subunit stoichiometry of two
α1 subunits and one each of β1, γ, and δ subunits(1). The nAChR has two agonist binding
sites located at the α/γ and α/δ subunit interfaces(2–4). The α subunits contribute the primary
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binding site components, termed loops A, B, and C, while the γ and δ subunits contribute the
complementary components, primarily loop D, with possible contributions from loops E and
F. The focus of the present work is on loops A and B of the α subunit.
Work over the past several years on acetylcholine binding protein (AChBP) orthologs from
mollusks has led to important new insights into the structures of Cys-loop receptor ligand-
binding domains(5–8). AChBP is a soluble, homopentameric protein produced in glial cells
that is homologous to the nAChR ligand-binding domain. Crystal structures of AChBP with
various agonists bound have established that the nAChR binding site is comprised of a box
of conserved aromatic residues. One of these conserved aromatic residues is a tryptophan on
loop B, W149 (Figure 1, 2). Previous studies by this lab established that this tryptophan
makes a strong cation-π interaction with ACh in the muscle-type receptor (9), and its role as
a component of the AChBP “aromatic box” confirmed those findings. Subsequent work
showed that the potent nicotinic agonist epibatidine also makes a cation-π interaction with
W149. (9, 10). Nicotine is a quite weak agonist at the muscle-type receptor; its actions at the
neuronal receptors are more substantial. As such, epibatidine is a better candidate for
studying interactions between non-ACh agonists and the muscle-type receptor.
The AChBP crystal structures suggest other important ligand-binding domain interactions
that require verification through experiment. One structurally interesting interaction involves
a conserved aspartate on loop A, D89 (we use the residue numbering that corresponds to the
nicotinic receptor, not the AChBP numbers)(6). This residue is part of a highly conserved
WxPD motif exhibited across the entire Cys-loop superfamily (Figure 1). In the crystal
structures of AChBP, D89 is positioned to interact with loop B through any of a number of
hydrogen bonds between the aspartate carboxylate side chain and loop B residues T148,
W149, and T150 (Figure 2). For the purposes of discussion, a schematic of the putative
hydrogen bonding network, labeling potential hydrogen bonds, is shown in Figure 3A. The
high conservation of the WxPD motif, and the clear interaction of D89 with a known
component of the agonist binding site (loop B/W149) have generated considerable interest
in D89. Note that loop A also contains a canonical contributor to the aromatic box, Y93
Recently, Lee and Sine(11) have investigated D89 and its role in agonist binding by
combining site-directed mutagenesis with single channel kinetic analyses. Neutralization of
the negative charge at position 89 through a mutation to asparagine or threonine (D89N and
D89T, respectively; Figure 3B) substantially compromised receptor function, producing
significant decreases in the bimolecular forward rate constant for agonist-receptor binding.
In contrast, mutating residues T148 and T150, singly and in combination, did not seriously
impact function. From these results, Lee and Sine concluded that D89 plays a structural role
in stabilizing loop B, in particular W149, for agonist association. They concluded that
essential structural features of the D89/loop B network were the negative charge of D89 and
hydrogen bonds between the aspartate carboxylate and the amide backbones of T150 and
T149 (hydrogen bonds i and ii of Figure 3A). They also proposed that a possible
polarization of the backbone carbonyl of W149 contributes to ACh binding(6).
In the present study, we sought to further probe the role of the conserved D89 in the nAChR
ligand-binding domain. Through the incorporation of unnatural amino acids using the
nonsense suppression methodology(12–14), we introduced more subtle modifications to the
side chain of D89, allowing what we have termed “chemical-scale” studies of such complex
receptors. By chemical scale we mean, in effect, the distance scale to which chemists are
accustomed: the functional group; the specific bond rotation or local conformational change;
the precise noncovalent interaction. We have also incorporated amide-to-ester backbone
mutations in loop B to probe proposed hydrogen bonds to this region. We conclude that the
significantly disruptive D89N mutation affects receptor function in several ways, including:
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a distortion of the hydrogen bonding network; the introduction of an electrostatic clash
between the asparagine amide side chain and the backbone amides of loop B; and, to a lesser
extent, a neutralization of charge. We also find that, of the network of hydrogen bonds
implied by the AChBP structure (Figure 3A), no one hydrogen bond is singularly important.
Rather, maintaining the overall network of hydrogen bonds and avoiding electrostatic and/or
steric clashes are essential for proper function. To support our unnatural amino acid
mutagenesis studies, we conducted molecular dynamics simulations of the wild-type and
D89N mutant ligand-binding domains to evaluate the hydrogen bonding network.
Materials and Methods
Synthesis of Wah cyanomethyl ester (3-(3-Indolyl)-2-hydroxypropanoic acid cyanomethyl
ester)
α-hydroxytryptophan (Wah) (3-(3-Indolyl)-2-hydroxypropanoic acid) cyanomethyl ester
was synthesized according to previously published methods(10, 15). The hydroxy acid (255
mg, 1.24 mmol) was dissolved in 1.9 ml of ClCH2CN (30 mmol) and 514 µl Et3N (3.65
mmol). Upon stirring under Ar for 45 min, the solution turned pale yellow. The reaction
mixture was concentrated and dried under vacuum. The material was dry loaded onto a flash
silica gel column and run in 9:1 methylene chloride/ethyl acetate to give 242 mg (80 %
yield) of hydroxyl-tryptophan cyanomethyl ester: 1H NMR (DMSO) δ 3.04 (m, 2H), 3.32
(broad s, 1H), 4.38 (broad s, 1H), 4.94 (s, 2H), 6.96 (t, 1H, J = 7.2 Hz), 7.05 (t, 1H, J= 6.9
Hz), 7.12 (d, 1H, J = 2 Hz), 7.32 (d, 1H, J = 7.8 Hz), 7.51 (d, 1H, J = 7.5 Hz) , 10.85 (s,
1H); 13C NMR 30.0, 48.9, 70.7, 109.7, 111.3, 115.8, 118.3, 118.3, 120.8, 123.8, 127.3,
136.0, 172.7: Electrospray MS Calcd for C13H12N2O3 plus H: 245.08. Found m/z (M+H):
245.0.
Synthesis of dCA-Wah
Hydroxytryptophan cyanomethyl ester (11 mg, 45 µmol) was dissolved in 315 µl dry DMF
in a flame-dried 5 ml round bottom flask with a stir bar. The dinucleotide dCA (20 mg, 16.7
µmol) was added, and the reaction stirred under Ar for 9 hours. Upon completion of the
reaction, the pure compound was obtained by preparative HPLC. Electrospray MS Calcd for
C30H35N9O15P2 minus H: 823.17. Found m/z (M-H): 822.0.
Synthesis of t-Butyl 2-Diphenylmethyleneimino-4-nitro-butanoate
Lithium diisopropylamide (6.8 mL 0.5 M in THF, 3.4 mmol) was added to a solution of N-
diphenylmethyleneglycine t-butyl ester (1 g, 3.4 mmol) in THF (6.8 mL) at −78°C. After 1
h, nitroethylene (4.25 mL 0.8 M in THF, 3.4 mmol), prepared from 2-nitroethanol as
reported previously(16), was added to the mixture and stirred for an additional 1 h. The
reaction was then brought to room temperature and a 1:1 mixture of ethyl acetate and water
(20 mL) was added. The organic layer was separated, washed with brine, dried (Mg2SO4),
and evaporated. Crude product was purified on a flash silica column using a 1:1 ethyl
acetate and hexane solvent system to yield 690 mg pure product (53%): 1H NMR (CDCl3) δ
1.44 (s, 9H), 2.58 (m, 2H), 4.08 (t, 1H), 4.53 (m, 2H), 7.20 (m, 2H), 7.36 (m, 3H), 7.47 (m,
3H), 7.67 (m, 2H); ES-MS calculated mass for C21H24N2O4: 368.17, Found m/z (M+H+):
369.0, (M+Na+): 390.8, (M+K+): 407.0.
Synthesis of nitrohomoalanine
t-Butyl 2-Diphenylmethyleneimino-4-nitrobutanoate was deprotected by adding 1 N HCl
and stirring for 15 h at room temperature. The reaction was lyophilized and taken onto the
next reaction.
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Synthesis of (NVOC)-nitrohomoalanine
Nitrohomoalanine (230 mg, 0.6 mmol) and Na2CO3 (132 mg, 1.2 mmol) were dissolved in
water (10 mL). To this solution, NVOC-Cl (171 mg, 0.6 mmol) in dioxane (10 mL) was
added and stirred for 4 h at room temperature. The reaction was evaporated to half of the
reaction volume and then diluted with 20 mL of water. The solution was extracted with ether
(20 mL) until the organic was no longer colored. The aqueous layer was acidified with HCl
to a pH ~2 (solution became cloudy) and extracted with dichloromethane until organic layer
was clear. The organic layers were dried and evaporated to yield 209 mg of (NVOC)-
nitrohomoalanine (90%); ES-MS calculated for C14H17N3O10: 387.09, Found m/z (M-H−):
387.0. Crude product was taken on directly to the next step.
Synthesis of (NVOC)-nitrohomoalanine cyanomethyl ester
(NVOC)-nitrohomoalanine (50 mg, 0.13 mmol) was dissolved in 5 mL ClCH2CN. Et3N
(18.3 µL, 0.13 mmol) was added and the solution was stirred under Ar for 4 h. The reaction
was evaporated and purified on a flash silica column with a 1:1 mixture of ethyl acetate and
hexanes solvent system to yield 40 mg of product (72%). 1H NMR (CDCl3) δ 2.95 (m, 2H),
3.18 (m, 2H), 3.96 (s, 3H), 4.02 (s, 3H), 4.33 (m, 1H), 4.96 (d, 2H), 5.56 (d, 2H), 5.72 (d,
1H), 6.91 (s, 1H), 7.72 (s, 1H). ES-MS calculated for C16H18N4O10: 426.10, Found m/z (M
+Na+): 449.0, (M+K+): 465.0.
Synthesis of Nha-dCA
(NVOC)-nitrohomoalanine cyanomethyl ester (10 mg, 2.3 µmol) was dissolved in 0.5 mL
dry DMF. The dinucleotide dCA was added (10 mg, 8.4 µmol) and stirred under Ar
overnight. The reaction was purified by reverse phase HPLC. ES-MS calculated for
C33H38N11O22P2: 1005.9, Found m/z (M-H−): 1004.2.
Synthesis of Akp-dCA
The synthesis of 2-amino-4-ketopentanoic acid and preparation of Akp-dCA was described
previously(17).
Unnatural Amino Acid Suppression
Synthetic amino acids and α-hydroxy acids were conjugated to the dinucleotide dCA and
ligated to truncated 74 nt tRNA as previously described.(15, 18) Aminoacyl tRNA was
deprotected by photolysis immediately prior to co-injection with mRNA, as described.(18,
19) Typically, 25 ng of tRNA were injected per oocyte along with mRNA in a total volume
of 50 nl/cell. mRNA was prepared by in vitro runoff transcription using the Ambion (Austin,
TX) T7 mMessage mMachine kit. The site of interest was mutated to the amber stop codon
by standard means, verified by sequencing through both strands. Mouse muscle embryonic
nAChR in the pAMV vector was used. A total of 4.0 ng of mRNA was injected in the
subunit ratio of 10:1:1:1 α:β:γ:δ. In all cases, a Leu-to-Ser mutation at a site 50 Å from the
nAChR ligand-binding domain in the M2 helix, known as 9’, was used to lower EC50 values
to a measurable range(10, 20). Previous work on this mutation has shown that a Leu9’Ser
mutation in the β subunit lowers EC50 values 40-fold without changing trends in EC50
values(13, 20). In addition, the α subunits contain an HA epitope in the M3–M4 cytoplasmic
loop for western blot studies. Control experiments show that this epitope does not detectably
alter EC50. As a negative control for suppression, truncated 74 nt tRNA or truncated tRNA
ligated to dCA was co-injected with mRNA in the same manner as fully charged tRNA. At
the positions studied here, no current was ever observed from these negative controls. The
positive control for suppression involved wild-type recovery by co-injection with 74 nt
tRNA ligated to dCA-Thr or dCA-Trp. Frameshift suppression at αD89 was utilized as
described by Rodriguez et. al.(21)
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Electrophysiology
Stage VI oocytes of Xenopus laevis were employed. Oocyte recordings were made 24 to 48
h post injection in two-electrode voltage clamp mode using the OpusXpress™ 6000A (Axon
Instruments, Union City, California). Oocytes were superfused with Ca2+-free ND96
solution at flow rates of 1 ml/min before application, 4 ml/min during drug application, and
3 ml/min during wash. Holding potentials were −60 mV. Data were sampled at 125 Hz and
filtered at 50 Hz. Drug applications were 15 s in duration. Acetylcholine chloride was
purchased from Sigma/Aldrich/RBI. Epibatidine was purchased from Tocris as (±)
epibatidine dihydrochloride. All drugs were prepared in sterile ddi water for dilution into
calcium-free ND96. Dose-response data were obtained for a minimum of 10 concentrations
of agonists and for a minimum of 3 cells. Dose-response relations were fitted to the Hill
equation to determine EC50 and Hill coefficient values.
Generation of Mouse Muscle nAChR Heteropentamer Computational Model
A model of the mouse muscle ligand-binding domain was created by first aligning the
mouse muscle nAChR sequence with the sequence of the Torpedo marmorata acetylcholine
receptor whose structure was solved using electron microscopy by Unwin(22) and resolved
to 4 Å resolution(23). An alignment was generated using the T-Coffee website. A homology
model was then built with this alignment using Prime(24), within the Schrödinger suite of
programs. The individual chains of the T. marmorata structure 2BG9 were used as templates
for each subunit type. Chain A of the T. marmorata structure was used as a template for both
α subunits of the mouse muscle nAChR. Each subunit was exported as a PDB file and
aligned in Swiss PDB Viewer(25). This structure was imported back to Prime where a
sidechain prediction algorithm was used.
This heteropentamer was converted to GROMACS(26) format and inserted in a periodic box
with 7 Å gaps between the protein and the box edge for molecular mechanics minimizations
and simulations. SPC water molecules(26) were used to add explicit solvation to the model
followed by the insertion of sodium and chloride ions to bring the molarity of the box to 150
mM. An excess of sodium ions was added to neutralize the charge of the protein.
Ligand Incorporation into Mouse Muscle nAChR Model
Using this heteropentamer, another structure was generated containing carbamylcholine
(CCh) in the two ligand-binding pockets of the mouse muscle nAChR. This was performed
by aligning the box residues of the mouse muscle model with the D binding site of the
AChBP structure containing CCh (1UV6). Gromacs parameters for the ligand (CCh) were
initially generated using ProDRG (http://davapc1.bioch.dundee.ac.uk/programs/prodrg/)
(27). The charges generated by ProDRG for CCh were modified due to a large positive
charge that was inaccurately placed on the nitrogen atom of the ammonium. Instead, ChelpG
charges from HF/6–31G calculations were used with some attenuation of the partial charges
between carbamoyl protons and oxygens to fit within GROMACS MD parameters.
Generation of the D89N Mutant Structures
D89N mutant structures were made from the homology model PDB file by mutating D89 of
both α subunits to Asn using Swiss PDB. The two structures differed in their orientations of
the NH2 of the side chain: D89N1 placed the NH2 in a position analogous to OD1 of D89 in
the wild type model, while D89N2 placed the NH2 in a position analogous to OD2. The
mutant models were then placed in a hexagonal periodic box and treated similarly to the
wild type model.
Molecular Dynamics Simulations. All four nAChR structures (agonist free wild type, CCh
bound wild type, D89N1, and D89N2) underwent one minimization step. Then, under the
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GROMACS forcefield, MD simulations were begun. The MD simulations started at 0 K and
warmed up to 310 K over the first 25 ps. The protein and drug (CCh bound structure) were
highly restrained during this warmup followed by 100 ps of slowly releasing the restraints.
All simulations after this point continued unrestrained for 5000 ps (wild type structures) or
7500 ps (D89N mutant structures).
Analysis of Molecular Dynamics Simulations
All molecular dynamics trajectories were analyzed using the tools included in the
GROMACS suite(26). All characterizations were performed on the final 500 ps of the
simulations. Each trajectory file contained data at 0.5 ps intervals, yielding 1000 frames of
analysis per simulation. Distances and hydrogen bonds were analyzed using the g_dist and
g_hbond programs, respectively. The default g_hond hydrogen bond structural cut-offs (a
donor/acceptor distance of 3.5 Å and an acceptor/hydrogen/donor angle of 30°) were used
when monitoring hydrogen bonds.
RMSD values for the CCh bound wild type, D89N1, and D89N2 simulations were
calculated using the g_rms program. All comparisons were made with respect to the average
loop B structure of the final 500 ps of the agonist free wild type simulation obtained from
g_cluster, using the gromos method and an rmsd cut-off of 0.14 Å. The α carbons of the two
structures to be compared were aligned prior to the rmsd calculation. Figure 8 was produced
from PDB files generated by g_cluster, using the above conditions on the agonist free and
CCh bound wild type simulation trajectories.
Results
Conventional Mutants, D89N and D89E
The present work evaluates receptors using the macroscopic parameter EC50, the effective
concentration of agonist necessary to achieve half-maximal response, rather than the more
information rich, but more time consuming, single-channel analyses of Lee and Sine(11).
We made this choice both in order to examine a large number of mutants and to avoid the
additional challenges of performing single-channel studies at the low expression levels often
associated with unnatural amino acid mutagenesis. Of course, EC50 is a composite value that
could be influenced by changes in agonist affinity or in gating. Since the mutations we are
evaluating are in close proximity to the agonist binding site and are quite remote from the
gate of the channel, we interpret changes in EC50 as affecting binding more than gating.
Consistent with this view, single channel analyses of several D89 mutants reveal much more
substantial changes in binding parameters than in gating parameters(11).
For comparison, we first studied two conventional mutants, D89N and D89E that were also
studied by Lee and Sine. The D89E mutant produced a modest 4-fold increase in EC50 for
both ACh and epibatidine. However, the D89N mutant produced much more substantial 23
and 28-fold increases in EC50 for ACh and epibatidine, respectively (Table 1). Our results
parallel the single channel work, in which D89N produced a significant decrease in rate
constants for ACh association while D89E resulted in a modest decrease in association rates
and barely any change in the overall agonist binding equilibria.
Unnatural Mutants, D89Nha and D89Akp
The essential role of D89 is confirmed by the large perturbation of the D89N mutant. While
generally considered a subtle change, an Asp-to-Asn mutation does more than simply
neutralize charge. It also replaces a hydrogen bond accepting O with a hydrogen bond
donating NH2, and in the present context this change introduces a possible electrostatic clash
between position 89 and loop B (Figure 3B). The amide side chain of asparagine places an
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Nδ−–Hδ+ bond dipole in close proximity to the Nδ−–Hδ+ bond dipoles of the loop B amide
backbone at T150 and W149. This possible repulsive interaction between the Nδ−–Hδ+
dipoles could contribute to the deleterious effects of the D89N mutant.
In an attempt to dissect apart these two features of the D89N mutant, we incorporated two
unnatural amino acids that neutralize the negative charge of Asp without introducing an
electrostatic clash. A nitro group (NO2) is isoelectronic and isosteric to a carboxylate, but it
has no negative charge (Figure 4). Also, a nitro group is a substantially weaker hydrogen
bond acceptor than carboxylate(28); the measured difference in energetics of carboxylate
and nitro hydrogen bonding is 1.5 – 2.0 kcal/mol(29), corresponding to a factor of 10–20 in
an equilibrium constant. The ideal residue would be nitroalanine, the nitro analog of Asp,
but it is not chemically compatible with the nonsense suppression methodology. Therefore,
we studied nitrohomoalanine (Nha), the nitro analog of Glu (Figure 5). Since the D89E
mutant produces only a modest change in receptor function, comparing the Nha mutant to
the Glu mutant was deemed meaningful.
Incorporation of Nha at position 89, D89Nha, resulted in a modest 4-fold increase in EC50
when compared to the isosteric D89E receptor for both ACh and epibatidine (Table 1). This
change is comparable to that of the original D89E mutation. The D89Nha mutant behavior
suggests that charge neutralization is no more deleterious than an increase in side chain
length at position 89.
The second neutral unnatural amino acid we incorporated was 2-amino-4-ketopentanoic acid
(Akp, Figure 5), producing D89Akp. Akp is a direct analog of Asp, and the ketone side
chain of Akp is sterically similar to the Asp and especially the Asn side chains (Figure 4).
However, Akp lacks the Nδ−–Hδ+ bond dipole (Figure 3C), and so does not contribute an
electrostatic clash. When Akp was incorporated at position 89, 8- and 10-fold increases in
EC50 were observed for ACh and epibatidine, respectively, relative to wild type (Table 1).
The ~2.5-fold difference in EC50 between the D89Akp and D89N receptors can be attributed
to the electrostatic clash produced by the Asn Nδ−-Hδ+ dipole.
Loop B Backbone Mutations
Of the four possible hydrogen bonds in the D89/loop B network, two involve side chain-to-
side chain interactions, and two involve hydrogen bonds with the loop B amide backbone
(Figure 3A). The side chain interactions (iii and iv) have been probed by conventional
mutagenesis(11). T148L, T150A, and T148L/T150A mutants were not substantially
disruptive, suggesting hydrogen bonds iii and iv are not crucial. By inference, the backbone
hydrogen bonds i and ii have been proposed to be especially critical to receptor function(11).
Probing backbone hydrogen bonds requires the power of unnatural amino acid mutagenesis.
Appropriate amide-to-ester mutations remove the backbone NH that can contribute to the
hydrogen bond (Figure 5B). In the present system, the T150Tah mutation disrupts hydrogen
bond i, and the W149Wah mutation disrupts hydrogen bond ii. The W149Wah mutation
produced very modest effects (Table 2), suggesting that hydrogen bond ii is nonessential.
The T150Tah mutation has been studied previously(10). It is unique among the mutations
considered here in that the results for ACh and epibatidine are qualitatively different; the
EC50 for ACh decreased ~3-fold, while that for epibatidine increased ~4-fold. Ester
backbones not only eliminate a hydrogen bond donor in the backbone; they also weaken the
corresponding (adjacent) carbonyl as a hydrogen bond acceptor. The carbonyl perturbed by
the T150Tah mutation, the W149 backbone carbonyl (H in Figures 2, 5B), points away from
the region being probed here and directly into the agonist binding site. Epibatidine can make
a hydrogen bond to this carbonyl, and the ester mutation weakens the hydrogen bond
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accepting ability of the carbonyl, accounting for the rise in EC50. No such hydrogen bond is
possible for ACh. As such, we consider ACh the better gauge of the importance of hydrogen
bond i, and we ascribe a nonessential role for it.
D89N and ester double mutants
Backbone ester mutations in loop B were also produced in an attempt to recover wild-type
receptor function from the D89N mutant. If indeed a Nδ−–Hδ+•••Hδ+–Nδ− dipole-dipole
clash is introduce by the D89N mutation, an appropriate backbone ester would not only
alleviate the clash, but would replace it with a potentially favorable hydrogen bond (Figure
3D). Two double mutants were evaluated, D89N/T150Tah and D89N/W149Wah (Table 2);
representative traces for the latter are shown in Figure 6. The D89N/T150Tah double mutant
(attempting to rescue hydrogen bond i) did not fully recover wild-type receptor function: 18-
and 5-fold increases in EC50 were observed for ACh and epibatidine, respectively. In
contrast, the D89N/W149Wah double mutant (attempting to rescue hydrogen bond ii; Figure
3D) produced near wild-type activity, with EC50 increases of only 2.7-fold and 1.3-fold for
ACh and epibatidine, respectively. These results suggest that there is an asymmetry in the
D89/loop B network that allows the electrostatic clash of the Asn side chain to be relieved
through an ester at position 149 but not at position 150. Note that the D89N/W149Wah
mutant receptor is an example of a receptor that contains no negative charge in the vicinity
of position 89, but retains nearly wild-type activity.
Molecular Dynamics Simulation of nAChR Ligand-binding Domain
We performed two simulations of the mouse muscle nAChR ligand-binding domain, one
without and one with the agonist carbamylcholine (CCh) bound. Other simulations of
AChBP and variants of the nAChR have appeared(30–35). The agonist free structure is
based on Unwin’s model of the receptor from T. marmorata, which is nearly identical in
sequence to the mouse muscle receptor. CCh was then docked into this structure in a manner
compatible with the crystal structure of AChBP that contains CCh in the agonist binding
site(6). We monitored hydrogen bonds i through iv, considering both oxygens of the D89
carboxylate (referred to as OD1 and OD2, Figure 8), for a total of eight possible
interactions. Along with the D89/loop B hydrogen bonds, we monitored two “control”
hydrogen bonds that are part of a well-defined α-helix in the ligand binding domain. The
results summarized in Figure 7 and Table 3 are calculated from the final 500 ps of the 5 ns
simulations.
The agonist-free structure shows a very well defined hydrogen bonding network. In a
representative structure (Figure 8A), one carboxylate oxygen (OD2) makes hydrogen bonds
to the two backbone NHs (i and ii), while the other carboxylate oxygen makes hydrogen
bonds to the two side chain OHs (iii and iv). These are strong hydrogen bonds, being present
more frequently than the reference hydrogen bonds of the α helix. Occasionally, one
carboxylate oxygen simultaneously makes three hydrogen bonds, and so on average there
are 4.7 hydrogen bonds between D89 and loop B. Note that the orientation of the
carboxylate in this simulation (Figure 2) differs from previous models, the side chain having
rotated to enable formation of four hydrogen bonds.
Addition of the agonist CCh leads to a reduced interaction between D89 and loop B. In the
agonist-free simulation, D89 interacts with all four loop B hydrogen bond donors in 94% of
the frames, but that number drops to 34% of the frames in the CCh-bound simulation.
Hydrogen bonds to the loop B backbone, interactions i and ii, are present less frequently in
the CCh-bound structure (decreases of 17% and 50%, respectively, in the number of frames
with a hydrogen bond present), while the side chain interactions, hydrogen bonds iii and iv,
remain. The average number of hydrogen bonds drops from 4.7 to 3.4 when agonist binds,
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and the distance between D89 and W149 increases from 4.3 Å to 5.1 Å (measured from the
D89 γ carbon to the W149 α carbon; Table 3). In the CCh-bound structure, OD1 makes the
majority of the interactions with loop B, while OD2 interacts only with the T150 hydroxyl
side chain (Figure 8B). Structurally, the changes between empty and occupied agonist
binding sites arise because the D89 side chain rotates to a less symmetrical arrangement that
favors one carboxylate oxygen over the other in hydrogen bonding (Figure 8). Also the T150
side chain reorients, but the OH group ends up in a similar location. In addition, as others
have noted, the side chain of W149 reorients to make a cation-π interaction with the agonist.
Simulations of the D89N mutant were performed on the agonist-free structure only, because
the Asn mutant mainly affected the kinetics of agonist association to the unbound
nAChR(11). Two simulations that differ in the initial orientation of the Asn side chain were
considered. In the D89N1 simulation, the N89 amide nitrogen was placed in a position
comparable to OD1 of the agonist-free wild type structure, while in D89N2, the nitrogen
was placed in the OD2 position.
As summarized in Table 3, both simulations show that the D89N mutant substantially
disrupts the interaction between position 89 and loop B. The average distance between N89
and loop B (measured from the N89 γ carbon to the W149 α carbon) over the final 500 ps
was larger for both D89N1 and D89N2 simulations (5.3 Å and 8.1 Å, respectively) than
either wild type simulation. Also, in the D89N mutant simulations the 4.7 hydrogen bonds
seen in the agonist free wild type simulation are reduced to ~1.5, and many of these
hydrogen bonds do not correspond to hydrogen bonds i–iv, but are new hydrogen bonds
involving the backbone of N89. The substantial disruption of the D89N mutant structures
can also been observed in the loop B region. A comparison between the final loop B
structure of the agonist free wild type simulation and comparable structures from the D89N1
and D89N2 simulations yielded RMSDs of 2.5 Å and 3.8 Å, respectively (Table 3).
Discussion
The study of the nAChR ligand-binding domain has been transformed by information gained
from the AChBP crystal structures. Structural interactions found in the AChBP crystal
structures have served as starting points for new mutation studies in the nAChR and other
Cys-loop family receptors(36, 37). However, since the AChBP is not an actual LGIC and
has < 25% homology to the closest nAChR relative, α7, experiments are necessary to test
the relevance of interactions found in the crystal structures. The use of unnatural amino
acids has allowed us to probe the relevance of these AChBP interactions at a chemical scale
unavailable with conventional mutagenesis(10, 12, 13, 20).
In the present study, we have evaluated the structural role of the highly conserved residue,
D89. According to the AChBP crystal structures, D89 provides the contact point between
loop A, which contains D89 and agonist binding site residue Y93, and loop B, which
contains the critical agonist binding site residue W149 (Figure 2). In the AChBP structures
the D89 carboxylate forms hydrogen bonds with the backbone amides of loop B residues
T150 and W149, while also interacting with the hydroxyl side chains of T148 and T150.
This network is conserved among the primary ligand-binding subunits of the Cys-loop
family of receptors (Figure 1). As noted before, D89 is part of a highly conserved WxPD
motif found in essentially all known Cys-loop receptors. The residues aligning with T148
are conserved as hydroxyl side chains, serine or threonine. W149 is part of the conserved
aromatic box that comprises the agonist-binding site. In three different Cys-loop receptors –
the nAChR considered here, the 5-HT3 (serotonin) receptor, and the GABAC receptor – the
aromatic residue that aligns with W149 makes direct contact with bound agonist through a
cation-π interaction. (9, 10) (20, 38).
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The essential role of D89 was established by the severe consequences of the relatively
modest mutation D89N, an effect reported previously(11). Such a mutation could disrupt
any or all of the 4 potential hydrogen bonds suggested by the AChBP structures (Figure 3).
Conventional mutagenesis previously showed that hydrogen bonds iii and iv could be
removed without significant disruption of receptor function. Using unnatural amino acid
mutagenesis, we have now ablated hydrogen bonds i (T150Tah) and ii (W149Wah), and
neither change is seriously disruptive. Clearly, no single hydrogen bond between loop B and
loop A is critical to receptor function.
Along with disrupting hydrogen bonding, the D89N mutation neutralizes the negative
charge of the wild type Asp. Others have concluded that binding of cationic agonists such as
ACh requires a negative charge in the loop A/loop B interface region. However, more subtle
charge-neutralization strategies, such as incorporation of Nha or Akp, do not reproduce the
full D89N effect. This suggests that another factor is operative.
Along with disrupting hydrogen bonds and neutralizing charge, we propose that the D89N
mutation introduces a destabilizing Nδ−–Hδ+•••Hδ+–Nδ− dipole-dipole clash. The other
charge neutralizing mutations, D89Nha and D89Akp, do not experience such a clash and so
are less disruptive. Also, the introduction into the D89N construct of a second, backbone
mutation that removes one of the offending Nδ−–Hδ+ dipoles (D89N/W149Wah) restores
near wild type behavior. This double mutant has no negative charge at the loop A/loop B
interface yet is near wild type in behavior.
Another proposed role for D89 is a polarization of the W149 carbonyl (H in Figure 2),
which points into the agonist binding site and can directly contact agonists(6). An amide
carbonyl is highly polarized Cδ+=Oδ−, and the partial negative charge on oxygen could
contribute to binding cationic agonists. It has been proposed that the negative charge of D89
could enhance this polarization(6), although we are unaware of any precedent for this type
of effect. Our results do not appear to support this suggestion. In the mutant T150Tah the
key carbonyl is much less polarized, as it is now an ester carbonyl rather than an amide
carbonyl. However, this mutation decreases ACh EC50, opposite to expectations from the
polarization suggestion.
The picture that emerges for the role of D89 is not simple. It seems certain that hydrogen
bonding between the side chain of D89 and loop A is involved. However, no one interaction
is singularly important. A subset of the full complement of interactions between D89 and
loop B is required to stabilize the nAChR ligand-binding site.
Another possible indication of the disruptive nature of the D89N mutation can be found
from a pair of Cys-loop receptors that are gated by serotonin. The 5-HT3 receptor has a Trp
that aligns with the nAChR Trp α149, and it makes a cation-π interaction with the agonist
serotonin.(20) Interestingly, the MOD-1 receptor from C. elegans naturally contains the
D89N substitution, a rare exception to the highly conserved WxPD motif. Also, even though
MOD-1 is highly homologous to the 5-HT3 receptor, and it binds the same neurotransmitter,
the cation-π interaction in MOD-1 has moved away from the loop B aromatic reside to a
different side chain of the aromatic box that is on loop C. (39) This could reflect the
disruption of loop B caused by the D89N substitution in MOD-1.
Molecular dynamics simulations generally support the experimental data of others and
ourselves. In our simulations, a sharp reduction of hydrogen bonding in the position 89/loop
B network suggests that the D89N mutation severely disrupts interactions between position
89 and loop B. In fact, in one of the D89N simulations, the Asn side chain ceases to interact
at all with loop B. Both D89N mutant simulations produced loop B structures that differed
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from their wild type counterparts. From these observations we conclude that loop B adjusts
in structure to accommodate the Asn.
From our molecular dynamics simulations of the mouse muscle nAChR ligand-binding
domain, it appears that D89 interacts with loop B more in the agonist-free state than in the
agonist-bound state. Relative to the agonist-free structure we find an average of ~one less
hydrogen bond between D89 and loop B; and D89 is almost 1 Å further from loop B in the
CCh-bound structure. Because loop B itself does not relocate substantially on agonist
binding (as revealed in the comparison of our agonist free and CCh bound wild type
simulations), the role of D89 is to preorganize the empty agonist binding site into a
conformation that favors binding, an effect that would enhance binding affinity(40).
Apparently, once the agonist is bound, the stabilization of loop B provided by D89 is no
longer necessary, and the interaction between the two weakens. This is consistent with an
earlier conclusion that the D89N mutation affects agonist association but not subsequent
steps in the channel activation mechanism(11).
In conclusion, chemical-scale studies of the D89/loop B network have further refined our
understanding of this interesting and highly conserved structural feature. D89 and loop B
form a redundant network of hydrogen bonding interactions, no one of which is essential. In
addition, the charge on D89 is not essential for receptor function. The D89N mutation both
disrupts the hydrogen bonding network and also introduces a repulsive electrostatic
interaction, significantly destabilizing the D89/loop B network. These results, along with
molecular dynamics simulations and earlier single channel studies(11), indicate that the role
of the D89/loop B network is to preorganize the agonist binding site for ligand binding, with
no significant contribution to the gating mechanism.
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Figure 1.
Alignments of portions of loops A and B for several Cys-loop receptors. The WxPD motif
of loop A and the region around W149 of loop B are highlighted. AChBP: ACh binding
protein from Limnaea stagnalis; mα1: nAChR α1 subunit of mouse muscle (studied here);
hα7: human nAChR α7 subunit; hGly-α1: human glycine receptor α1 subunit; h5-HT3A:
human 5-HT3 A subunit.
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Figure 2.
Region investigated in the present work. Loop A is shown in blue; loop B in green.
Highlighted are the side chains of D89, T148, and T150, which together can form a network
of hydrogen bonds. Also shown are contributors to the agonist binding site: Y93 from loop
A; W149 side chain and W149 backbone carbonyl (red star) from loop B. This carbonyl and
the side chain of Trp 149 point directly at the agonist, which in this view lies “behind” loop
B. This image results from MD simulations, as discussed in text.
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Figure 3.
Schematics of potential hydrogen bonding interactions between loops A (blue) and B
(black). A. The wild type receptor. B. D89N, highlighting the potential electrostatic clash. C.
D89Akp; note the lack of an electrostatic clash. D. The double mutant D89N/W149Wah;
note how hydrogen bond ii could, in principle, be restored.
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Figure 4.
Functionalities of the side chains considered here, shown as space-filling models. Note the
greater steric similarity between Asp and Nha and between Asn and Akp.
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Figure 5.
A. Natural and unnatural amino (and hydroxy) acids considered here. B. Consequences of
incorporating an α-hydoxy acid into a protein. The critical ester linkage is highlighted in
bold; the carbonyl that is modulated is noted with a star.
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Figure 6.
Representative dose-response relations (A) and fits to the Hill Equation (B). Where errors
bars are not evident in the fits, they are smaller than the markers. The receptor is the D89N/
W149Wah double mutant.
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Figure 7.
Analysis of hydrogen bonding in the molecular dynamics simulations of the nAChR ligand-
binding domain without (A) and with (B) CCh bound. Hydrogen bonds were monitored
between both D89 carboxylate oxygens (OD1, white bars, and OD2, black bars) and the four
loop B hydrogen bond donors. C. Control hydrogen bonds between the backbone amide of
K10 and the backbone carbonyl of R6 (K10R6, white bar) and the backbone amide of L11
and the backbone carbonyl of L7 (L11L7, black bar) were also monitored in both structures.
All observations were made during the final 500 ps of the 5 ns simulations. Data expressed
as the percentage of the 1000 observed frames where a given hydrogen bond was present.
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Figure 8.
Two views of hydrogen bonding interactions for the receptor without (A) and with (B) CCh
bound. Generated with the g_cluster progran of the GROMACS suite from the final 500 ps
of the 5 ns nAChR ligand binding domain simulations.
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Table 3
Molecular Dynamics Simulationsa
D89-Loop B Distance (Å)b Number of D89-LoopB
Hydrogen Bondsc
RMSDd
WT Agonist Free 4.3 ± 0.2 4.7 ± 0.8 --
WT CCh Bound 5.2 ± 0.3 3.4 ± 0.8 1.5 ± 0.2
D89N1 5.3 ± 0.3 1.6 ± 0.6 2.5 ± 0.1
D89N2 8.1 ± 0.5 1.5 ± 0.9 3.8 ± 0.3
a
All statistics averaged over the final 500 ps of the given simulation (1000 frames) and presented as mean ± standard deviation of the mean.
b
Distance measured from D89 or N89 γ carbon to the W149 α carbon.
c
All hydrogen bonds between position 89 and loop B residues, T148, W149, and T150. Includes both oxygens of D89 in wild type simulations.
d
RMSD calculated in reference to the average structure from the final 500 ps of the agonist free wild type simulation. Average structure from
g_cluster program of GROMACS suite.
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